CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Average Recommendation of “Buy” from Brokerages

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Rating) has been given a consensus recommendation of “Buy” by the eighteen research firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, five have given a hold rating and nine have given a buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $129.08.

Several equities research analysts recently commented on the company. Royal Bank of Canada cut their target price on CRISPR Therapeutics from $117.00 to $95.00 and set a “sector perform” rating on the stock in a research report on Wednesday, February 16th. StockNews.com assumed coverage on CRISPR Therapeutics in a research report on Thursday, March 31st. They set a “sell” rating on the stock. Citigroup cut their target price on CRISPR Therapeutics from $90.00 to $64.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 15th. The Goldman Sachs Group cut their target price on CRISPR Therapeutics from $179.00 to $87.00 and set a “neutral” rating on the stock in a research report on Thursday, February 17th. Finally, Truist Financial restated a “buy” rating and set a $220.00 target price on shares of CRISPR Therapeutics in a research report on Wednesday, February 16th.

Shares of CRSP stock opened at $51.96 on Thursday. The stock’s fifty day simple moving average is $61.09 and its 200 day simple moving average is $71.89. CRISPR Therapeutics has a twelve month low of $50.54 and a twelve month high of $169.76. The firm has a market capitalization of $3.98 billion, a P/E ratio of 11.76 and a beta of 2.02.

CRISPR Therapeutics (NASDAQ:CRSP – Get Rating) last released its quarterly earnings results on Monday, February 14th. The company reported ($1.84) EPS for the quarter, missing analysts’ consensus estimates of ($1.74) by ($0.10). CRISPR Therapeutics had a net margin of 41.28% and a return on equity of 16.21%. The company had revenue of $12.90 million during the quarter, compared to the consensus estimate of $5.39 million. On average, sell-side analysts anticipate that CRISPR Therapeutics will post -7.69 earnings per share for the current fiscal year.

Several institutional investors have recently modified their holdings of CRSP. Capital Impact Advisors LLC purchased a new stake in shares of CRISPR Therapeutics in the fourth quarter worth approximately $26,000. Elkhorn Partners Limited Partnership raised its stake in shares of CRISPR Therapeutics by 180.0% in the fourth quarter. Elkhorn Partners Limited Partnership now owns 350 shares of the company’s stock worth $27,000 after purchasing an additional 225 shares during the last quarter. Kistler Tiffany Companies LLC grew its holdings in shares of CRISPR Therapeutics by 6,250.0% in the fourth quarter. Kistler Tiffany Companies LLC now owns 381 shares of the company’s stock valued at $29,000 after acquiring an additional 375 shares in the last quarter. Larson Financial Group LLC grew its holdings in shares of CRISPR Therapeutics by 160.6% in the third quarter. Larson Financial Group LLC now owns 271 shares of the company’s stock valued at $30,000 after acquiring an additional 167 shares in the last quarter. Finally, CI Investments Inc. bought a new position in shares of CRISPR Therapeutics in the third quarter valued at approximately $30,000. 55.21% of the stock is owned by hedge funds and other institutional investors.

CRISPR Therapeutics Company Profile (Get Rating)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Further Reading